• February 28, 2007 - The Role of the False Claims Act in Combatting Medicare & Medicaid Fraud by
  Drug Manufacturers: An Update
  A new report (PDF) by Andy Schneider of Medicaid Policy, LLC reports that over $3.9 billion has been recovered from drug manufacturers over the course of the last 6 years as a result of just 16 cases brought by False Claims Act whistleblowers.  All six of the cases brought in the last two years involve fraud against Medicaid, and all were initially brought to the attention of the U.S. Government by whistleblowers.  Over 180 false clams act cases against drug manufacturers are now under investigation by the U.S. Department of Justice.  >> To read the study and the release
  
   

• July 17, 2006 - Fighting Medicare Fraud:  More Bang for the Federal Buck New TAF report calculates that fighting healthcare fraud using the False Claims Act's whistleblower provisions returns $15 back to the U.S. Government for rvery $1 invested in enforcement and prosecution. (press release)
  
   

• False Claims Act and Qui Tam Quarterly Review is TAF's compendium of legal developments, providing an overview of major False Claims Act and qui tam developments, including case decisions, DoJ interventions, and settlements.
  
  
  

• Advising the Qui Tam Whistleblower: From Identifying a Case to Filing under the False Claims Act, by Robin Page West, co-published by Taxpayers Against Fraud and the American Bar Association. (contact us to request copies)
  
  
  

• TAF Report:  Investments Pay Dividends
  A new study by Jack Meyer, President of the Economic and Social Research Institute, finds that every dollar invested by the government in False Claims Act health care investigations and prosecutions returns $13 back to the American people.  >> To read the study and the release
  
   

• TAF Report: $2.4 Billion is Tip of Drug Fraud Iceberg
  A new study by Andy Schneider of Medicaid Policy, LLC reports that over $2.4 billion has been recovered from drug manufacturers engaged in fraud against the U.S. Government and the 50 states. "This is just the tip of the iceberg," notes James Moorman, President of the TAF Education Fund. "The Department of Justice reports that over 500 drugs are under investigation right now, and we believe many very large fraud cases are still under seal."
  >> To read the study and the release
  
  

• Reducing Medicare and Medicaid Fraud by Drug Manufacturers, by Andy Schneider, Medicaid Policy, LLC
  
  
  

• Reducing Medicaid Fraud: The Potential of the False Claims Act, by Andy Schneider, Medicaid Policy, LLC
  
  
  

• Fighting Medicare Fraud: More Bang for the Federal Buck, by Jack Meyer, New Directions for Policy
  
  
  

• Reducing Health Care Fraud: An Assessment of the Impact of the False Claim Act by Jack Meyer and Stephane E. Anthony, New Directions for Policy, October 1, 2001
  
  
  

• TAF 10th Anniversary Report

Publications from the U.S. GAO GAO: CMS’s Commitment to Helping States Safeguard Program Dollars Is Limited, June 28, 2005   GAO: MEDICARE:  CMS Did Not Control Rising Power Wheelchair Spending, April 28, 2004   GAO: Medicare Fraud and Abuse: DOJ Continues to Promote Compliance with False Claims Act Guidance, April 8, 2002 GAO: Medicare Fraud and Abuse: DOJ Has Improved Oversight of False Claims Act Guidance, March 29, 2001 GAO: Medicare Fraud and Abuse: DOJ Has Made Progress in Implementing False Claims Act Guidance, November 17, 2000 GAO: Medicare Fraud and Abuse: DOJ's Implementation of False Claims Act Guidance in National Initiatives Varies, August 11, 1999